index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

94

 

NOTICES

155

 

 

MOTS CLES

Biological therapy Accelerometer Anxiété Endocrine toxicity Anticancer drugs Auto-Diagnostic Adolescent Abus d'antibiotiques Sacroiliitis Immune checkpoint inhibitors Antibiotic misuse Bacterial rhinosinusitis Azathioprine COVID-19 Méta-Analyse Adalimumab Pregnancy Pharmacoepidemiology Antibiotics Network meta-analysis Dermatology Graft-versus-host disease Alitretinoin Bacterial Cardiotoxicity Antimicrobial resistance Drug reaction Psoriatic arthritis Epidemiology Spondyloarthritis Spondylitis Placebo Anti-Bacterial Agents Autoimmune diseases Drug survival Antimicrobiens Sipuleucel-T Psoriasis Pharmacovigilance Arthritis Antibiotic resistance Quality of life Ethics Anti-HCV Direct Acting Antivirals DAA Axial spondyloarthritis Management Biologic drug Cardiomyopathy Beta-lactam antibiotics Biological Therapy Ankylosing Immunotherapy Treatment Acute Myeloid Leukaemia AML Intensive care Antimicrobials Etanercept Burden Systematic review Immune-related adverse events Amyloidosis Vigibase® Angiotensin-converting enzyme inhibitors Autoimmunity Meta-Analysis Biosimilar Pharmaceuticals Infliximab Anxiety Biologic Cardio-oncology Biomarkers Prostate cancer Apre-milast BTK protein Addiction Adverse side effects Cancer Pharmaco-Épidémiologie Biologics Albinism Aging Access to care ASDAS Alcohol Primary adrenal insufficiency Auto-immune hepatitis Ankylosing spondylitis Angiotensin receptor blockers Antimicrobial Stewardship Stability Atopic dermatitis Biologic therapy Atrial fibrillation Anti-TNF ArtThese Arrhythmia Apremilast Ustekinumab Biomédicaments Glucocorticoids

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS